A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer

International Journal of Cancer

Volumn 130, Issue 1, 2012, Pages 71-82

  Naderi, Ali ^a   Liu, Ji ^a   Francis, Glenn D ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

BEX2; breast cancer; c Jun; ErbB2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN BEX2; PROTEIN C JUN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; COHORT ANALYSIS; CONTROLLED STUDY; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MUTANT; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CHROMATIN IMMUNOPRECIPITATION; FEEDBACK, PHYSIOLOGICAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 80255137067     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25977     Document Type: Article

References (39)

1. Naderi A, Teschendorff AE, Beigel M, Cariati M, Ellis IO, Brenton JD, Caldas C,. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-κB inhibition of apoptosis in breast cancer cell lines. Cancer Res 2007; 67: 6725-36. (Pubitemid 47105519)
2. Naderi A, Liu J, Bennett IC,. BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 2010; 126: 1596-610.
3. Rohrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H,. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer 2009; 8: 86.
4. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R,. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 2009; 11: 485-96.
5. Naderi A, Liu J, Hughes-Davies L,. BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer. Mol Cancer 2010; 19: 111.
6. Deng X, Gao F, May WS,. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 2009; 113: 422-8.
7. Tsuchiya A, Tashiro E, Yoshiro M, Imoto M,. Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1in leptomycin B-inhibited cyclin D1expression. Oncogene 2007; 16: 1522-32. (Pubitemid 46398746)
8. Seznec J, Weit S, Naumann U,. Gene expression profile in a glioma cell line resistant to cell death induced by a the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53-the role of NF-κB. Carcinogenesis 2010; 31: 411-8.
9. Foltz G, Ryu GY, Yoon JG, Nelson T, Fashey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z, Ryken TC, Vibkakar R, et al. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 2006; 66: 6665-74. (Pubitemid 44085623)
10. Jacobs TW, Gown AM, Yazji H, Barnes MJ, Schnitt SJ,. Specificity of Herceptest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-7. (Pubitemid 29318825)
11. Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC,. High concordance between IHC and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 2008; 21: 1271-7.
12. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ,. Suppression of Oncogene-induced transformation by a deletion mutant of c-jun. Oncogene 1993; 8: 877-86. (Pubitemid 23087418)
13. Brown PH, Chen TK, Birrer MJ,. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 1994; 9: 791-9. (Pubitemid 24065917)
14. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y,. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15: 254-64. (Pubitemid 26029205)
15. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Listanti MP, Pestell RG,. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010; 285: 8218-26.
16. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH,. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res 2008; 1: 45-55.
17. Yuan G, Qian L, Song L, Shi M, Li D, Yu M, Hu M, Shen B, Guo N,. Heregulin-b promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells. Mol Cell Biochem 2008; 318: 73-9.
18. Matsui K, Sugimori K, Motomura H, Ejiri N, Tsukada K, Kitajima I,. PEA3 cooperates with c-Jun in regulation of HER2/neu transcription. Oncol Rep 2006; 16: 153-8.
19. Ginestier C, Adelaide J, Goncalves A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, et al. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 2007; 26: 7163-9. (Pubitemid 350059680)
20. Naderi A, Liu J,. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett 2010; 298: 74-87.
21. Hofsli E, Wheeler TE, Langaas M, Laegreid A, Thommesen L,. Identification of novel neuroendocrine-specific tumour genes. Br J Cancer 2008; 99: 1330-9.
22. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, et al. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13: 62-9. (Pubitemid 46067387)
23. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, Sakamaki T, Katiyar S, Jia X, Popov VM, Yu Z, Wu K, Joyce D, et al. Nuclear Factor-κB Enhances ErbB2-Induced Mammary Tumorigenesis and Neoangiogenesis in Vivo. Am J Pathol 2009; 175: 1910-20.
24. Yang JW, Lee EY, Kang KW,. ErbB2 overexpression in p53-inactivated mammary epithelial cells. FEBS Lett 2006; 580: 6501-8. (Pubitemid 44750930)
25. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffery SS,. P53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9: R30.
26. Yamashita H, Nishio M, Toyma T, Sugiura H, Zhang Z, Kobayashi S, Iwase H,. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004; 6: R24-30.
27. Kayahara M, Wang X, Tournier C,. Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-O- tetradecanoylphorbol-13-acetate responsive element and myocyte enhancer factor 2 binding sites. Mol Cell Biol 2005; 25: 3784-92. (Pubitemid 40559583)
28. Olayioye MA,. Intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001; 3: 385-9. (Pubitemid 34196365)
29. Moasser MM,. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007; 26: 6469-87. (Pubitemid 47530601)
30. Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, Huaser CA,. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-κB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J Biol Chem 1996; 271: 7992-8. (Pubitemid 26108618)
31. Jin X, Song X, Li L, Wang Z, Tao Y, Deng L, Tang M, Yi W, Cao Y,. Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma. Mol Carcinog 2007; 46: 901-11. (Pubitemid 350058410)
32. Zhang D, Li J, Wu K, Ouyang W, Ding J, Li ZG, Costa M, Huang C,. JNK1, but not JNK2, is required for COX-2 induction by nickel compounds. Carcinogenesis 2006; 28: 882-91.
33. Hollywood DP, Hurst HC,. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-ErbB-2 in mammary tumour lines. EMBO J 1993; 12: 2369-75. (Pubitemid 23194187)
34. Pasleau F, Grooteclaes M, Gol-Winkler R,. Expression of the c-ErbB2 gene in the BT474 human mammary tumor cell line: measurement of c-ErbB2 mRNA half-life. Oncogene 1993; 8: 849-54. (Pubitemid 23087415)
35. Vernimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, Winkler R,. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 2003; 370: 323-9. (Pubitemid 36259446)
36. Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F, De Bortoli M,. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 2000; 19: 280-8. (Pubitemid 30077225)
37. Ailan H, Xiangwen X, Daolong R, Lu G, Xiaofeng D, Xi Q, Xingwang H, Rushi L, Jian Z, Shuanglin X,. Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells. BMC Cancer 2009; 9: 279.
38. Han C, Liu H, Liu J, Yin K, Xie Y, Shen X, Wang Y, Yuan J, Qiang B, Liu YJ, Peng X,. Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex. Nucleic Acids Res 2005; 33: 6555-65. (Pubitemid 41806420)
39. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH,. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Biol Cell 2003; 23: 9003-13. (Pubitemid 37499791)